Bowen Tian

Director

I am leading the effort in the LNP mRNA process development, including:

• Set up the first PD lab within Catalent in GOS, Belgium
• Design and deliver process development for LNP mRNA
• Generate strong proof-of-concept data for LNP mRNA process development
• Support business development and client meetings and visits
• Co-lead of team to support LNP mRNA process development at GOS, Belgium
• Maintain vigilant for LNP and RNA related technology development
• Scientific leader in early-stage projects related to non-viral delivery systems

Senior Scientist

• I am leading the efforts in the design and development of LNP formulation for gene delivery (e.g. mRNA) using highly innovative automated microfluidics systems.
• I am the thought leader in the LNP gene delivery field and actively involved in media interview, publications, online seminar, conference presentation, and commercial and client (first tier) facing roles

Head of Protein Science

I am leading the efforts to set up labs with following capabilities, as follows:.

• Gene engineering:viral vector and plasmid design and production,gene sequencing.
• Protein expression and engineering: affinity maturation and stability maturation.
• Cell line engineering: single cell sequencing, mammalian display

Scientist

• Discovery and engineering of novel antibodies for CAR-T cell.
• Screen CAR-T interaction with target cells.
• Protein production to support R&D projects and animal immunization.
• Novel technology development to study cell-cell interactions.
• Engineering novel modalities for T-cell activation.
• Schrodinger Molecular Modelling in drug discovery

Senior Scientist

• Assay development for the screening of T-cell receptors with various affinity (uM to pM) binding to the target peptide-HLA, including protein expression and characterization, binding assay development and imaging.
• The development T-cell receptor based diagnostic reagents for peptide-HLA complex detection and quantification in cells and tissues, including companion diagnostics (e.g. CDx)design and development, protein expression and characterization, bio-imaging

Research Fellow

• Nanoparticles for safer and more efficient delivery of radionuclides into cancer (funded by Wellcome Trust Pathfinder Award). The project has led to a patent(application number: GB1604220.2).
• Commercialzing a novel drug delivery platform technology.
• Nanosensors integrated bioreactors for regenerative medicine.
• Microfabricated cantilever methods as nanoscale screens for early indicators of protein aggregation

The School of Pharmacy, University College London

The School of Pharmacy, University College London

Shenyang Pharmaceutical University